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INTRODUCTION 
        Menorrhagia  is defined as bleeding that originates from the uterus
 
. In 
developing countries, the majority of cases are due to fibroid uterus. Massive 
menorrhagia is a major clinical and surgical problem with a mortality of 80%, 
which is most often related to hemodynamic instability.
3,4
 
Uterine fibroids are the most frequent tumors of the female genital tract, 
occurring in 20–50% of women who are older than 40 years. Uterine fibroid, 
the most common cause of nonacute abnormal uterine bleeding, is also the 
most common solid uterine neoplasm occurring in 20–40% of all women 
during their reproductive  period
10
.  
Uterine artery embolization (UAE) was introduced in the 1970s to treat 
postpartum hemorrhage
14. 
In the 1990s, this technique was successfully used 
preoperatively 3–10 days before myomectomy to reduce bleeding during the 
surgical phase
14
. In 1995, Ravina et al.
15
 proposed embolization of uterine 
arteries as an alternative to surgical treatment of uterine leiomyoma. 
MASSIVE MENORRHAGIA  : 
A) DEFINITION 
Menorrhagia is defined as heavy or prolonged uterine bleeding that 
occurs at regular intervals. Some sources define menorrhagia further as the loss 
of ≥ 80 mL blood per cycle or bleeding > 7 days.  
B) CLINICAL CONSIDERATIONS 
               Conservative management of massive menorrhagia carries a mortality 
rate of 50%–100%5  and the mortality is up to 35% even in patients undergoing 
operation
6
. Surgery remains the procedure of choice in the treatment of massive 
menorrhagia caused by specific conditions, such as dysfunctional uterine 
bleeding, hypertension, and endocrine etiology, that is resistant to other 
therapies
12
. 
           Embolization has become a first-line treatment for symptomatic uterine 
fibroid
8   .
Therapeutic uterine artery embolization is a good treatment adjunct to 
control uterine bleeding and reduces the need for high-risk hysterectomy
7
.  
UAE may help to avoid surgery in patients who are not good surgical 
candidates. Should menorrhagia recur in these patients, repeat embolization can 
be performed safely
10
. Even in surgical candidates, UAE is effective in 
preparing the patient for elective rather than high-risk   surgery
7
. 
The goal of uterine fibroid embolisation is to stop blood flow to the 
uterus through the uterine arteries, thus depriving myomas of their blood 
supply
9 
to produce ischemic
 
infarction . 
Various non uterine systemic arteries, as well as ovarian arteries, may 
also contribute to menorrhagia, and their implication is dependent on the 
underlying location of fibroid
13,14,15,16,17,18
. Non Uterine systemic collateral 
vessels must be particularly suspected when there is evidence of larger size of 
fibroid
11,19
. Recognition and occlusion of Non Uterine systemic collaterals 
providing blood to hypervascular fibroid  lesions is essential for successful 
percutaneous embolotherapy of fibroid 
2,17,18,19,20
. Prior to embolization, the 
interventional radiologist needs to be aware of the dominant side of the uterine 
artery bleeding, and the most likely source of bleeding has to be identified to 
determine which vessel is to be occluded. Since the uterine  circulation is the 
most frequent source of menorrhagia, embolization of uterine arteries is usually 
the favored therapeutic option to stop the bleeding
11,21 
. 
Recent important technologic advances in three dimensional color 
doppler sonography,   have introduced a comprehensive, noninvasive method 
of evaluating the entire uterus, allowing detailed assessment of the vascularity 
and volume of fibroid
1,2
. Three dimensional color doppler sonography can also 
help in the planning of a focused and efficient non uterine systemic artery 
embolization. It provides a precise road map for the interventional radiologist  
in performing an endovascular treatment for menorrhagia. Uterine artery 
embolization leads to good technical  success and fibroid volume reduction
10
.  
The aim of this study was to evaluate the effectiveness of three 
dimensional color Doppler sonography in assessment of volume and 
vascularity reduction of fibroids treated by uterine artery embolisation. 
 
 
  
AIM OF THE STUDY 
The purpose of the present study is to prospectively evaluate the   
accuracy of three-dimensional color doppler sonography in depicting changes 
in fibroid volume and vascularity of  pre and post uterine artery embolisation in   
patients undergoing treatment of  fibroid. 
REVIEW OF LITERATURE 
RELEVANT ANATOMY 
Branches of internal illac artery is given below, 
                                  Internal illac artery 
Branches of  Anterior 
divisions 
Branches of  Posterior divisions 
Superior vesical  
Uterine artery  
Middle rectal  
Obturator  
Internal pudendal artery  
Inferior gluteal artery  
Superior gluteal artery  
Illiolumbar  artery  
Lateral sacral artery 
 
 
Uterine Artery  is the first branch of anterior division of internal iliac 
artery .  It has 3 segments  
 Descending segment goes along pelvic wall 
 Transverse segment goes to the midline 
 Ascending segment along the uterus 
 
 COMMON  VARIANTS  IN  BRANCHING  OF  
INTERNAL  ILLAC  ARTERY 
 
 
The uterus is  supplied by a single arterial vascular system composed of   
the uterine artery, which account for 99% of the arterial blood supply to the 
uterus. Uterine artery has a characteristic U shape with descending segment 
that parallels lateral pelvic wall , a transverse segment that crosses the distal 
ureter at the level of cervix and a ascending segment that courses along the 
uterine margin  at the edge of the broad ligament  
The uterine vasculature feeding the uterus is situated close to the ovarian 
arteries and the two systems are connected by anastomoses.  
NORMAL AND VARIANT ARTERIAL SUPPLY TO THE UTERUS  
Normal arterial anatomy and variants are the key to the uterine artery 
embolisation.  
Normal variants : abdominal aorta  origin , <1% congenital absence of 
botn uterine arteries. 5- 10% can have retrograde utero – ovarian anastomosis  
of size less than 500micrometer 
Possible variation in uterine artery; 
 Cervico vaginal artery 
 Perforating arteries, terminal branches to the fallopian tubes and 
ovaries 
 Inferior vesicle artery has common origin 
 Can have completely or partially absent uterine artery which can 
be bilateral.  
Ovarian artery : anteromedial origin from  abdominal aorta shows 
characteristic cork screw appearance in angiogram . 5- 10 % of ovarian artery 
may supply uterine fibroid. 
Other sources of fibroid supply is from : 
Round ligament artery and lumbar artery which necessitates flush 
aortography after embolisation that identifies specific feeding artery. 
Identification of the normal arterial anatomy and main variations in 
uterine fibroid tumor vascularization are key to the safety and success of the 
procedure
22  
Ovarian supply to the leiomyoma should be excluded by placing 
the tip of the catheter at L1 level during initial flush aortogram. If discovered, 
ovarian artery can also be safely embolized
55
.  
Special mention : 
Pedunculated subserosal fibroid may have arterial pedicle from adjacent 
illac, renal or aortic branches. After embolisation it may separate from uterus 
and drift into peritoneal cavity
55
.Bicornuate uterus may be supplied by one 
uterine artery only
 
. 
Differential diagnosis 
1. Endometrial polyp with a single feeding vessel from an 
intracavitary submucosal fibroid. 
2. Adenomyosis is distinguished by rain drop appearance, multiple 
scattered vessels or intratumoral vascularity, but fibroid has 
feeding from  peripheral vessels. 
3. EMBOLOTHERAPHY: 
Embolization is defined as the "therapeutic introduction of various 
substances into the circulation to occlude selective vessels, either to arrest or 
prevent haemorrhage, to devitalize a structure, tumour or organ. 
UAE- EMBOLIC AGENTS: 
There are two different embolic agents   used commonly  
1. Permanent  embolic agent is polyvinyl alcohol particles (PVA). 
2. Temporary embolic agent is gelfoam. 
Polyvinyl alcohol particles  (PVA): 
 PVA is the most often used embolic agents in patients with 
uterine fibroids.  
 PVA is permanent embolic agent is injected to occlude 
predominantly peri - fibroidal arterial plexus seen surrounding 
the fibroid . 
 Varying  Particle sizes of 355-500 µm and 500-710 µm are 
available commercially. Commonly used particle size is of 355-
500 µm. 
GELFOAM (GELATIN SPONGE) : 
 Following gelfoam is injected to occlude the main uterine artery . 
 Gelfoam (gelatin sponge) is the most commonly used material. It 
is a readily available, slowly resorbable material that can be used 
as individual pledgets, torpedoes, or part of a slurry. For initial 
distal occlusion, 0.5- to 2.0-mm cubes can be used followed by 3- 
to 4-mm pledgets or torpedoes for more proximal occlusion. 
Gelfoam pledgets are mixed with dilute contrast within a1 - or 3-
ml syringe. Since the Gelfoam pledgets float within the contrast 
saline solution, the tip of the syringe should be pointed upward. A 
theoretical disadvantage of Gelfoam particles is that their 
resorption may lead to more rapid recanalization and recurrent 
bleeding.    
Three-Dimensional Color Doppler Sonography in pre and post Uterine 
Artery Embolisation of Fibroids : 
Arthur C. Fleischer,   Edwin F. Donnelly, et al. Three-Dimensional 
Color Doppler Sonography (3D CDS)  before  and  after  fibroid  embolization  
2000
9
. Quantitated 3D CDS provides global depiction of the small arteries and 
veins within the fibroid and provides an estimate of completeness of 
embolization. 3D CDS can be used to for predict which patients will be 
responders or nonresponders. 12 of 31 fibroids were hypervascular, 10 of 31 
were isovascular, and 9 of 31 were hypovascular. Of the 12 hypervascular 
fibroids, 10 (83%) became reduced in volume by 50%, whereas only 4 of 10 
(40%) isovascular  fibroids and 2 of 9 (22%) hypovascular fibroids  decreased 
in volume by 50%. 
Sangeet Ghai, MD, Dheeraj K. Rajan, et al
 
. Uterine artery embolization 
for leiomyomas: Pre and post procedural evaluation with ultrasound (US), 
2005
46
. US is a readily available first-line imaging modality and a well-
accepted method for both pre- and postprocedural evaluation of patients who 
undergo UAE. Follow-up imaging is performed at 3, 6, and 12 months after 
UAE to quantify volume reduction in the uterus and leiomyoma. Volume 
reduction of the dominant fibroid is greater than that of the uterus, and follow- 
up US has shown a reduction in uterine size of up to 40%, with the dominant 
fibroid decreasing in size by up to 70% (9,39,40). The majority of fibroid 
shrinkage occurs within a 6-month period following embolization, with further 
reduction in size occurring between 6 and 12 months. 
C. Joseph Muniz, MD, Arthur C. et al
6 
states that the Three-dimensional 
Color Doppler Sonography and Uterine Artery Arteriography of Fibroids 
Assessment of Changes in Vascularity Before and After Embolization, 2002 .  
In 13 (87%) of 15 patients there was agreement; in 2 (13%) of 15 there was 
disagreement. In both cases of disagreement, three-dimensional color Doppler 
sonography showed collateral flow not depicted by uterine artery arteriography. 
The mean reduction in quantitated vascularity after uterine artery embolization 
was 44% (range, 19%–78%). Three-dimensional color Doppler sonography 
accurately depicts fibroid vascularity and in some cases can reveal collateral 
flow not depicted by uterine artery arteriography. 
Jean-Pierre Pelage, Julien Cazejust, et al
 
2005
23
. Uterine Fibroid 
Vascularization and Clinical Relevance to Uterine Fibroid Embolization, 
Identification of the normal arterial anatomy and main variations in uterine 
fibroid tumor vascularization are key to the safety and success of the 
procedure. 
Kitamura,   Susan   M   Ascher, et al. Imaging Manifestations of   
Complications Associated with Uterine Artery Embolization, 2005
28 
Fibroids 
in contact with the endometrial surface, including submucosal fibroids or 
intramural  fibroids with a submucosal component, pose an increased risk  for 
fibroid passage. Women over 45 years of age are at increased risk  for ovarian 
dysfunction after UAE, because they  have a higher prevalence of uterine-
ovarian arterial anastomoses (43% of cases)  compared  with  women  under  
45  years  of age (5%).          
Suhny Abbara, Boris Nikolic et al 2007
54
. Frequency and extent of 
Uterine Perfusion via Ovarian Arteries observed during Uterine Artery 
Embolization for Leiomyomas, Of the visualized ovarian arteries (n = 88), 52% 
(46/88) were smaller than, 25% (22/88) were equal to, and 23% (20/88) were 
larger than the diameter of a 5-French catheter. The aortogram revealed that 
61% (54/88) of the ovarian arteries extended into the pelvis, whereas 38% 
(33/88) did not. Selective injections were performed in 54 ovarian arteries. Of 
these, 69% (37/54) of the ovarian arteries had residual fibroid perfusion from 
the ovarian arteries after UAE (10 left-sided, 15 right-sided, six bilateral = 37 
ovarian arteries). 
Jean-Pierre Pelage et al, 2005
23 
Regular PVA particles do not 
completely occlude the lumen of the occluded arteries because of their irregular 
shape and heterogeneous calibration and occlusion is completed by thrombus 
formation. For uterine fibroid, the recommended diameter is 700–900µm 
(compared to 500–700µm tris-acryl microspheres) for PVA microspheres and 
900 µm for hydrogel polyzene-F microspheres. 
Kenneth Murphy, et al 
27 
  has given that non target embolization of   
should be avoided to minimize the risk of postembolization sexual dysfunction. 
the aim of embolization is not to occlude the UA, but to occlude vessels that 
supply the fibroid(s) while sparing perfusion to the normal uterus proper. 
Bruce McLucas, Rita Perrella, et al 2002
4
,  Role of Uterine Artery 
Doppler  Flow in  Fibroid Embolization,  Initial peak systolic velocity was 
positively correlated with the size and shrinkage of myomas and uterine 
volume. Peak systolic velocity was positively correlated with the size and load 
of embolization particles and was significantly lower (mean, 33.2 cm/s) in 
patients with adenomyosis than those  without adenomyosis (mean, 39.3 cm/s). 
High peak systolic velocity (>64 cm/s) was a significant predictor of failure. 
Postembolization peak systolic velocity (mean, 21.85 cm/s) was significantly 
lower than preembolization peak systolic velocity (mean, 40.33 cm/s) and was 
not correlated with uterine  fibroid embolization variables. 
TP Jain, DN  Srivastava,  RP Sahu, et  al,  (2007)
23 
clearly demonstrated 
Uterine artery embolization for symptomatic fibroids with imaging  follow  up, 
All 32 patients had successful procedures. Overall, 25 patients responded, 
giving a clinical success rate of 78.12%. Mean reduction in volume of uterus 
and fibroid was 33 and 59.7% and 48.9 and 75.5% on US at 3 and 12 months 
respectively, and 33.3 and 58.6% on MRI at 3 months. Volume reduction on 
US and MRI at 3 months was highly correlative.
 
E. Aitken, A. Khaund, et al 2006, 
10
 the normal human myometrium  has  
a vascular  spatial  gradient  absent  in small fibroids, A quantitative gradient 
within the myometrial vascular system, which is absent in fibroids, has been 
demonstrated. These structural differences between diseased and healthy 
tissues are probably because of differing expression of angiogenic growth 
factors. Regarding UAE common indications are Symptomatic Fibroids and 
Post Partum Haemorrhage  
Uterine ischemia causes pain so limited embolisation is essential, Julien  
Cazejust, et al 
22  
Drs.Lussenhop and Spence
 
 first occluded a cerebral 
arteriovenous malformation under radiographic and catheter guidance in 1960. 
Charles Dotter is acknowledged as founder of the specialty from his landmark 
work on angioplasty, first published in circulation in 1960. Another who 
contributed early was Dr. Baum, who developed techniques for controlling G-I 
bleeding using Vasopressin.
 
Potential Complications  
 The common UAE complications are :       
Premature menopause 2-5% 
Expulsion of fibroid < 1% 
Sepsis < 1% 
Emergent hysterectomy Nil 
Death Nil 
 
Following Drs.Lussenhops and Doppman in the USA, Japanese 
physicians developed selective catheter techniques for treating spinal cord 
AVMs. In 1972, Dr. Dotter and Dr. Rosch
35
 again developed techniques for 
controlling bleeding due to ulcer disease by embolizing autologous clots. 
Dr.White et.al first used this technique successfully in 1974 to actually control 
ulcer bleeding with the survival of patient survived. Early in the 1970s, many 
radiologists began to use embolotherapy for lifesaving haemorrhages. 
Since 1960's, embolization of uterine artery has been used to treat post 
partum haemorrhage. Uterine artery embolisation was used to control heavy 
bleeding from cervical carcinoma. A recent case report from Ottawa hospital, 
Canada
 
 says that uterine artery embolisation was used to control bleeding from 
cervical pregnancy. The embolic agents used are polyvinyl alcohol,  acryilic 
spheres,  gelfoam, steel coils and these are approved by the U.S. Food and 
Drug Administration (FDA) for this purpose. 
Uterine Artery Embolization for fibroid uterus was first used as a 
technique to limit blood loss during surgical removal of fibroids, and 
performed well before the surgery. However, it was found that after 
embolization and while awaiting surgery many patients no longer had 
symptoms and frequently the operation itself proved to be unnecessary. UAE 
was introduced as a treatment for fibroids in 1992 in Paris by Dr. Jacques-
Henri Ravina, a gynaecologist. The treatment was first performed in the U.S. at 
the University of California at Los Angeles (UCLA). There are now many such 
centres on the world performing UAE to treat uterine fibroids.  Mahmood et 
al
32
 (2002) from Department of Vascular and Interventional Radiology, 
Stanford University analyzed the outcomes of 111 consecutive patients
 
who 
underwent abdominal myomectomy (n = 44) or fibroid embolization (n =67) 
over a 30-month period. The respective
 
observed success rates in abdominal 
myomectomy and uterine fibroid
 
embolization patients were 64% versus 92% 
for menorrhagia (p
 
< 0.05), 54% versus 74% for pain (not significant), and 
91%
 
versus 76% for mass effect (p < 0.05). The complication rates were 25% 
(abdominal myomectomy) and 11% (uterine fibroid embolization) (p < 0.05). 
The respective secondary end points for the two
 
procedures were 2.9 versus 0 
days mean hospital stay, 8.7 versus
 
5.1 days of narcotics use, and 36 versus 8 
days until resumption
 
of normal activities. These differences were all 
statistically
 
significant. He concluded that uterine fibroid embolization was a 
less invasive and safer treatment option in women with symptomatic 
leiomyomas
 
than myomectomy. Menorrhagia may be better controlled with 
embolization and myomectomy may be a better option in patients with 
mass
 
effect. Both procedures were equally effective in controlling
 
pain. 
Spies (1999)
52
 from Georgetown University Medical Centre presented 
results of 61 patients who underwent uterine fibroid embolization. During a 16-
month period menstrual bleeding was improved in 89%, with 81% of patients 
moderately to marked improvement.  Pelvic pain and pressure was improved in 
96% of patients, with moderate to marked improvement in 79%.  At initial 
imaging follow-up (mean, 4.4 months post procedure), median uterine volume 
decreased 34% (P = .0001) and the median dominant fibroid volume decreased 
50% (P = .0001). Imaging at 1 year (mean, 12.3 months) after the procedure 
showed continued reduction with a median uterine volume reduction of 48%   
(P = .0002) and median dominant fibroid volume decrease of 78% (P = .0002). 
The authors concluded that UFE appears effective in controlling symptoms and 
substantially reducing fibroid volume with few complications. 
Pron et al
 
(2003)
38
 reported on the Ontario Uterine Fibroid Embolization 
Trial, which enrolled 555 women. The median follow-up was 8.9 months. 
Menorrhagia improved in 83% of women following the procedure, 
dysmenorrhea improved in 77% and urinary frequency improved in 86% of 
women. The mean fibroid volume reduction for the dominant fibroid was 33% 
at 3 months. Amenorrhea occurred in 8% of women. The complication-related 
hysterectomy rate in the Ontario UFE Trial was 1.5% within 3 months of the 
embolization.12 of the 8 procedures, 2 were for infection, 4 for persistent post 
embolization pain, 1 for a 10 cm prolapsed leiomyoma, and 1 for persistent 
vaginal bleeding. 
Spies J, et al 
 
(2004)
50
 done a multicenter control trail comparing the 
Outcome of Uterine Embolization and Hysterectomy for Leiomyomas. Study 
published in American Journal of Obstetrics & Gynaecology. Spies J, et al 
states that shorter hospital stay with UFE: < one day versus Hysterectomy 2.3 
days. Return to work UFE: 10.7 days versus Hysterectomy: 32.5 days and 
Fewer complications (after 30 days) UFE: 12.7% versus Hysterectomy: 32% 
Jain et al  (2004) 
21
from All India Institute of Medical Sciences, New 
Delhi carried out a study to determine the effectiveness of uterine artery 
embolization (UAE) as a primary treatment of symptomatic fibroids. Study was 
carried out in total of 32 patients aged 25–49 years (mean 40.9 years). 
Procedure was carried out through unilateral femoral puncture using poly vinyl 
alcohol (PVA) particles 355–500 µm in size. All 32 patients had successful 
procedures. Overall, 25 patients responded, giving a clinical success rate of 
78.12%. Mean reduction in volume of fibroid was 59.7% (range 31.6–83.3%) 
and 75.5 %( range 46.2–96.8%) on USG at 3 and 12 months. He concluded that 
uterine artery embolization leads to good technical success and fibroid volume 
reduction. 
Tranquart  et al (2005)57 from France evaluated the sonographic feature 
of 58 women following uterine artery embolization and to assess the efficacy of 
embolization as the primary treatment of fibroids. Most patients were improved 
or free of symptoms at 3 months (90%), 6 months (92%) and 1 year (87%) and 
all monitored patients were free of symptoms at 2 years. Clinical failure of 
treatment occurred in only two cases (3%). Progressive significant reduction in 
fibroid size with reference to the baseline was demonstrated during follow-up 
from 3 months (29%) to 24 months (86%). He concluded that uterine artery 
embolization was a valuable endovascular method for the treatment of fibroids, 
resulting in marked reduction in fibroid size and disappearance of intrafibroid 
vessels without reduction in uterine vascularisation  
Albert. J. Smeets et al  (2009)
3 
from Department of Radiology of St. 
Elisabeth Ziekenhuis in Netherlands evaluated the controversial issues of 
Uterine artery embolization (UAE) in patients with a large fibroid burden 
.Seventy-one consecutive patients (mean age, 42.5 years; median, 40 years; 
range, 25–52 years) with a large fibroid burden were treated by UAE between 
August 2000 and April 2005. There were no serious complications of UAE. 
During a mean follow-up of 48 months (median, 59 months; range, 6–
106 months), 10 of 71 patients (14%) had a hysterectomy. Mean volume 
reduction of the fibroid and uterus was 44 and 43%. Mean infarction rate of the 
fibroid and overall fibroid infarction rate was 86 and 87%. In the vast majority 
of patients there was a substantial improvement of symptoms. Clinical results 
were similar in patients with a dominant fibroid >10 cm and in patients with 
large uterine volumes by diffuse fibroid disease. Their results indicate that the 
risk of serious complications after UAE in patients with a large fibroid burden 
was not increased. Moreover clinical long-term results are as good as in other 
patients who are treated with UAE. Therefore a large fibroid burden should not 
be considered a contraindication for UAE. 
In another article on Uterine Fibroid Embolization Goodwin13 and Spies 
highlight few contraindications to the procedure like pregnancy, suspected 
cancer, active infection indeterminate endometrial or adnexal abnormalities. 
They also cite the U.K. Hysterectomy or Percutaneous Embolisation for 
Uterine Leiomyomata  (HOPEFUL)
19
 study, which showed 2.6% incidence of 
septicaemia after uterine fibroid embolization, with 1.1% of the women 
requiring emergency hysterectomy. Severe infection, often necessitating urgent 
hysterectomy, was a rare but well-established complication of uterine fibroid 
embolization. 
The Fibroid registry
26
 (Fibroid Registry for Outcomes Data) of 3160 
patients showed an emergency hysterectomy rate of only 0.09% at 30 days. 
Emergency hysterectomy for bleeding has been described 4 months after 
uterine fibroid embolization. 
In the Randomized Clinical Embolization versus Hysterectomy (EMMY) 
27 trial, researchers in The Netherlands found those six weeks after treatment, 
women who underwent UFE reported higher satisfaction scores than those 
who had hysterectomies. Two years later, 90 percent of the women in both 
categories said they were satisfied with their therapies, the researchers 
reported in the March 2008 edition of Radiology. 
Ninety percent of women who underwent UFE avoided a hysterectomy, 
said Scott Goodwin, M.D,
 48
 the lead author and a professor and chair of the 
Department of Radiological Sciences in the School of Medicine at the 
University of California, Irvine. Study results were published in the January 
2008 issue of Obstetrics & Gynaecology. 
Research at Georgetown University
 
till 1999, 20.000 to 25,000 patients 
has had this procedure world-wide. Their initial results, along with those that 
have been published or presented at scientific meetings, says that symptomatic 
improvement in 85-90% of patients with the large majority of patients 
markedly improved. The improvement rate was similar for heavy menstrual 
bleeding and for pressure and pain symptoms. Most patients have rated this 
procedure as very tolerable and in almost all cases hospitalization is necessary 
for only one night. In some centres, the patients are treated and discharged the 
same day. The expected average reduction in the volume of the fibroids is 40-
50% in three months, with reduction in the overall uterine volume of about 30-
40%. Over time, the fibroids continue to shrink. With several years follow-up 
now available, it appear that fibroids which are successfully treated does not re 
grow. 
Giovanna Tropeano et al
11
 from Department of Obstetrics and 
Gynaecology, University Catholic del Sacro Cuore, Italy reports 
 
50–60% 
reduction in fibroid size and 85–95% relief of symptoms  following UAE. UAE 
offered shorter hospital stays (1–2 days for UAE versus 5–5.8 days for 
hysterectomy) and recovery times (9.5–28 days for UAE versus 36.2–63 days 
for surgery) and major complication rates (2–15% for UAE versus 2.7–20% for 
surgery, in 3 Randomised control trials. 
 
Four studies analysing cost-
effectiveness found UAE more cost-effective than surgery. There is insufficient 
evidence regarding fertility and pregnancy outcome after UAE. They 
concluded that good quality evidence supports the safety
 
and effectiveness of 
UAE for women with symptomatic fibroids.
 
The current available data are 
insufficient to routinely offer
 
UAE to women who wish to preserve or enhance 
their fertility. 
Hayden Homer
16 
Department of Obstetrics and Gynaecology, Institute 
for Women’s Health, University College London has said that data on 
pregnancy following uterine artery embolisation
 
(UAE)
 
are scarce, with just 
over 200 pregnancies reported. Two small prospective
 
trials
 
of UAE versus 
surgical intervention suggest increased levels
 
of adverse pregnancy outcomes 
following fibroid embolisation. This study suggests that in the absence of more 
robust evidence, caution should be
 
exercised
 
in recommending UAE to women 
who wants to retain their reproductive ambitions.   
Joao and Marisa
 
 (2010) 
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studied on pregnancy out come after uterine 
fibroid embolisation. This study shows comparable fertility rates between the 
two primary uterus-sparing treatments uterine fibroid embolization (UFE) and 
surgical myomectomy, which is considered the gold standard for symptomatic 
fibroids in women who wish to conceive. Of the 743 patients who received 
UFE treatment, 74 wanted to conceive and had been unable. Most women 
opted for UFE as a fertility treatment after failure of myomectomy or in vitro 
fertilization or because hysterectomy was the only suggested option. Of the 
74 women who wanted to become pregnant, 44 of them became pregnant 
(59.5%). There are five (11.3%) ongoing pregnancies and 39 (88.7%) finished 
pregnancies, with 33 successful live births (84.6%), four spontaneous 
abortions (10.3%), one induced abortion and one stillbirth. There were 22 
caesarean deliveries (66.6%), two preterm deliveries at 36 weeks (6.1%) and 
five low birth weights. This study concluded that in the future, UFE will 
probably be a first-line treatment option even for women who wish to 
conceive and are unable due to the presence of uterine fibroids. 
Rashid. S. et al 
40 
studied the effects of Uterine Artery Embolisation and 
Surgical Treatment on Ovarian Function in Women with Uterine Fibroids. 
Some studies have shown that patients treated with UAE develop amenorrhea 
(with rates varying from 1%–8% and as high as 14%) and have increased 
follicle-stimulating hormone (FSH) levels (within the menopausal range) 
suggesting ovarian dysfunction may occur as a consequence of UAE. This 
study compares the effects of UAE and surgery on ovarian function and 
menstrual cycle characteristics in women with uterine fibroids. The impact of 
age on ovarian function was also studied. All surgical patients had ovarian 
conservation at the time of surgery. Ovarian function assessed by the levels of 
serum FSH were measured on day 3 of the menstrual cycle before treatment, 
and at 6 and 12 months post-treatment and menstrual cycle characteristics. No 
significant difference was found between the two treatment groups in the rate 
of ovarian failure at 12 months (UAE: 11% versus surgery: 18%; P = 0.44. 
These findings provide no evidence that UAE accelerates deterioration in 
ovarian function at 1 year, in comparison with surgery.        
Van der Kooij SM et al  (2010) 58 from Department of Radiology, Academic 
Medical Center, Amsterdam compared the clinical outcome and health related quality 
of life (HRQOL), 5 years after uterine artery embolization (UAE) or hysterectomy in 
the treatment of menorrhagia caused by uterine fibroids. Patients with symptomatic 
uterine fibroids who were eligible for hysterectomy were assigned randomly 1:1 to 
hysterectomy or UAE. Endpoints after 5 years were re-intervention rates, menorrhagia 
and HRQOL measures that were assessed by validated questionnaires. UAE had a 
positive effect both on urinary and defecation function.  
MATERIALS AND METHOD 
30 patients (mean age, 31.67 years, age range 26-35years) referred to 
our institution in a six-month period for endovascular treatment of menorrhagia 
underwent  three dimensional color Doppler as  part of pre and post therapeutic 
evaluation.   
Study Design: Prospective   interventional  trial 
Study Place: Barnard Institute of Radiology, Madras Medical College. 
Collaborating Unit: Institute of Obstetrics and Gynaecology,  
Madras Medical College, Chennai. 
Study Population: Women with symptomatic fibroid 
Sample Size: 30 Women with symptomatic fibroid. 
METHODOLOGY : 
Patient Selection Criteria 
* Inclusion criteria :  
1. Women with symptomatic fibroid (menstrual disturbances or 
pressure symptoms due to size or pain) who want to retain their 
uterus and avoid surgery.  
2. Solitary or multiple intramural fibroids of less than 7 cm.  
3. Parous women who completed family and age less than 40 yrs.  
4. Ultrasound findings without any degeneration of fibroid  
5. Women who gave consent to undergo uterine artery embolisation 
and participate in study.  
* Exclusion criteria : 
1. Women with asymptomatic fibroid.  
2. Infertile women or parous women who want to conserve uterus 
for future pregnancy. 
3. Fibroids of more than 7 cm or with degenerative changes or 
hypovascular  in Doppler study.  
4. Sub mucous or pedunculated Sub serosal fibroid.  
5. Associated pelvic / adnexal and endometrial pathologies  . 
6. Previous history of anaphylaxis to contrast. 
7. Renal function test abnormality. 
8.  Systemic illness like HIV, HbsAg +ve, abnormal renal profile, 
Coagulation disorders. 
 Preoperative work up 
 History, pelvic exam . 
 Basic blood investigations done including Hb%, CBC, Blood 
Urea, Serum creatinine, HIV, HbsAg, Coagulation profile (BT, 
CT,PT,PTT). 
 FSH (day 3 ) to assess ovarian reserve 
 USG  of Pelvis  and  abdomen  done to know the location, size, 
number and volume of fibroid. Those who had degeneration 
(calcification or cystic degeneration) are excluded from the study.  
 Doppler USG done to know the vascularity of fibroid. Hypo 
vascular fibroids are excluded from study.  
 Fractional curettage performed to rule out any associated 
malignant changes in endometrium. 
 Pap smear to rule out cervical carcinoma. 
 Informed consent  
Procedural sequence: 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
PATIENTS WERE REFERRED FOR UTERINE ARTERY 
EMBOLISATION  AFTER  PRE OPERATIVE WORK UP   DONE  IN 
INSTITUTE OF OBSTETRICS AND GYNAECOLOGY.(n=30) 
PRE PROCEDURE THREE DIMENSIONAL ULTRASOUND AND COLOR 
DOPPLER SONOGRAPHY WAS DONE TO ASSESS  VOLUME  AND 
VASCULARITY OF THE FIBROID  FOR STANDARDISATION . 
 
Volume categorisation  in cu.cm  -  small (<50), medium (50- 150),large(>150) 
Vascularity – hyper or hypovascular fibroid 
 
SUBJECTED TO UTERINE ARTERY EMBOLISATION UNDER IV  
SEDATION  VIA UNILATERAL TRANS FEMORAL APPROACH 
IMMEDIATE POST PROCEDURE THREE 
DIMENSIONAL COLOR DOPPLER  SONOGRAPHY  
. 
 FURTHER FOLLOW UP EVALUATION WAS DONE AT 3,6,12 
MONTHS PERIOD AND FINDINGS ((n=27) WERE CORRELATED 
IF FIBROID SIZE IS MORE THAN 7 CM AND  
HYPOVASCULAR  IS ELIMINATED FROM THE STUDY 
UNILATERAL  UAE (n=19) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BILATERAL  UAE (n=11) 
 
GELFOAM  MIXED IN  IV 
CONTRAST (OMNIPAQUE) 
WAS  INJECTED (n=14) 
PVA  AND GELFOAM MIXEDWITH 
IV CONTRAST (OMNIPAQUE) WAS 
INJECTED (n=16) 
CHECK PELVIC   ARTERIOGRAM WAS DONE TO 
CONFIRM UTERINE ARTERY  OCCLUSION 
Clinical symptoms : 
In this prospective study 30 patients (n=30) with fibroid uterus having at 
least one of the following symptoms were selected. 
Symptoms related to leiomyomas were classified into three categories:  
 abnormal bleeding (menorrhagia, metrorrhagia),  
 Pressure symptoms like (Increased frequency of urination, lower 
abdominal heaviness, Constipation, uni-or bilateral hydronephrosis),  
 Pelvic pain. 
SONOGRAPHIC EXAMINATIONS : 
 All 30 patients were screened with a 3.5-MHz three dimensional trans 
abdominal ultrasound probe, SIEMENS ACUSON ANTARES PREMIUM 
EDITION ultrasound machine with  Siemens C7F2 4D Array probe (Fig5.1).   
 * Three Dimensional Transabdominal Ultrasound: to confirm  and 
to assess the size, location, number,  volume of   fibroids.  
 * Three Dimensional Color Doppler Sonographic assessment of the 
fibroid vascularity is done. Vascularity of fibroid was classified 
as hypervascular and hypovascular. Hypovascular fibroid 
patients are eliminated from this study. 
FIG 5.1: SIEMENS ACUSON ANTARES PREMIUM EDITION                                                                    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Siemens C7F2 4D Array -  
Three dimensional color 
Doppler sonographic probe 
 
Siemens CH4 – 1 convex probe  - 
Two dimensional color Doppler 
sonographic probe 
UTERINE ARTERY EMBOLISATION : 
    Patients selected according to the inclusion criteria were taken up for 
uterine artery embolisation (UAE) after adequate counselling. Eligible patients 
were advised to use contraception before the procedure and LMP confirmed. 
PATIENT PREPARATION: 
History of any medications ? 
Any allergies, especially to contrast materials. 
Any recent illnesses or other medical conditions. 
If there is any possibility for pregnancy. 
Nil oral previous night prior to the procedure. 
1. All patients were  explained about the procedure  and its possible 
complications.  
2. They were also informed about alternative  treatment options 
available.  
3. Written consent was obtained  from all patients. 
 Informed consent obtained from all the patients before the procedure. 
Patient has to be shaved in both groins & axillary region if femoral pulse 
is absent; clotting time, bleeding time, blood urea, serum creatinine levels 
should be within  normal limits . 
PROFORMA  : See annexure 
PRE PROCEDURE : 
This examination is usually done as an inpatient procedure in our 
hospital. 
PROCEDURE: 
Patient position : Supine 
Pre Anaesthetics 
 Inj Dexamethasone 8mg I.V Stat 
 Inj. Pheniramine Maleate I amp I.M Stat  
 Inj. Atropine Iamp I.V.Stat 
Anti biotic prophylaxis: 
* Inj Ampicillin 1gm I.V (ATD)  
Anesthesia/ Sedation : 
 Inj Tramadol 1 amp IM 
 A nurse or technologist will insert an intravenous (IV) line into a small 
vein premedication is given (1cc of atropine &1cc of phenramine maleate). 
 Small dose of sedative is given through the IV to lessen the anxiety of 
the patient during the procedure. 
Approach    :  Percutaneous right or left trans femoral approach. 
PROCEDURE : 
Uterine artery embolisation technique  done in our hospital  
 Angiography and Embolisation was performed using an SCHIMADZU, 
JAPAN 800mA  conventional angiographic unit with digital dicom 
fluoroscopy (FIG 5.2 ) 
 (A). With aseptic precautions under local anaesthesia femoral puncture 
was made. A line is drawn from the anterior superior illac spine to the 
pubic symphysis & 1 cm below the midpoint of the line, a point  is 
marked. Local anaesthetic given by keeping the middle finger &index 
finger the pulse is felt. A small incision in the skin is made & the 
subcutaneous tissue is separated with the artery forceps. By using the 
Seldinger’s technique, Seldinger single puncture needle (FIG 5.3), is 
used to puncture the artery. When the spurt of blood comes out of the 
needle,  the guide wire (FIG 5.5) is inserted through the needle with help 
of   the introducer. Once the  guide wire is inserted upto  the abdominal 
aorta  by  applying pressure at  the puncture site, the seldinger needle & 
the introducer SET (FIG 5.4)  is removed. Then the sheath connected 
with dilator is introduced over  the guide wire & inserted into the artery.  
 (B) A 4- or 5-Fr pigtail catheter placed at L1 level was used for flush 
aortogram initially to detect any aberrant supply to the uterus
10
.  
 Internal iliac artery catheterized with single multipurpose 4F-5F Roberts 
uterine curve catheter (FIG 5.6). 
 Pelvic arteriography with iv contrast omnipaque (FIG 5.5) is done to 
identify whether the supply is from unilateral or bilateral uterine arteries. 
 Superselective catheteterisation of Contra-lateral uterine artery was 
done. 
  
 Free flow embolisation was performed just beyond the junction of the 
horizontal and descending portions of the uterine arteries (keeping the 
tip of the catheter little bit far of  to block the entire feeding vessel) 
using   poly vinyl alcohol as the embolic agent. Following which 
absorbable gelatine sponge shavings was injected . 
 PVA particles sized 355–500 µm (FIG 5.8) have been used successfully 
in my study.
 
 
  In all  patients, 2 to 8 gelatin sponge pledgets (FIG 5. 7) were used to 
cap off the particulate embolization in the main uterine arterial trunk. 
 Avoid reflux, nontarget embolization to  preserve flow in the main 
uterine and ovarian arteries 
 Catheter withdrawn up to ipsi-lateral common iliac artery then passed 
into ipsi-lateral internal iliac and ipsi-lateral uterine artery. Embolisation 
done on the ipsi-lateral side. 
 Stagnation of contrast medium was evidenced in the uterine capillary 
network at the end of embolisation, and an absence of flow was depicted 
in the uterine artery by injecting contrast medium into hypogastric 
arteries.  
UAE- EMBOLIC AGENTS 
 
   
 
  
 
 
 
 
 
 
 
 
                                              
FIG.5.2  SCHIMADZU 800mA DIGITAL DICOM 
FLUOROSCOPY 
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FIG 5.6: CATHETERS 
COBRA CATHETER  
 
RENAL DOUBLE CURVE 
(RDC) CATHETER 
 
ROBERTS UTERINE 
CURVE (RUC)  
CATHETER 
 
PIGTAIL CATHETER 
 
 
  
  
          
 
 
 
 
 
 
   EMBOLIC AGENTS 
 
FIG 5.7: GELFOAM 
   
 
FIG 5.8: POLY VINYL ALCOHOL PARTICLES 
   
 
Endpoint of Embolisation  
 Occlusion of the identifiable vessels supplying the fibroids while 
antegrade flow is maintained in the main uterine artery
 
giving the pruned tree 
appearance. 
* Evidence of “standing column of contrast” in the uterine artery and 
reflux towards the uterine origin or into the internal iliac artery. 
 
* Cessations of flow in the ascending uterine artery with residual flow in 
the lower uterine segments supplying the normal myometrium  
Adverse Complications: 
We had subintimial dissection in 2 patients while performing  
catheterisation of  ipsilateral/  contralateral internal illac artery . 
Fortunately we have not had Vessel perforation / Inadvertent embolisation 
of other organs or  / Allergic reaction. 
Post procedure events: 
Post procedure : 
 All 30 patients were subjected to immediate (within an hour) of post 
embolisation ultrasonography and  colour Doppler study . 
 Three Dimensional Transabdominal Ultrasound  to assess the size and 
volume of fibroid, and the presence of embolic agents within the fibroid.  
 
 Three Dimensional Color Doppler Sonographic assessment of the fibroid 
vascularity was done. Hypovascularity in the embolised fibroid patients  
was  noted.  
Post procedure monitoring : 
Patients were observed in high dependence ward for 6 hrs then at least 48 
hrs in the routine wards. All the patients were carefully observed for any 
complications like groin haematoma /retroperitoneal haematoma. Vitals were 
checked. Patients were kept nil per oral for 4 hours. They were advised bed rest 
for 6 hours and then ambulated. Patients were discharged after 48-72 hrs.  
On discharge:  
        Patients were advised to report  if  appearance of new symptoms like   
 Any   unbearable  lower abdominal pain  
 Fever or Purulent vaginal discharge 
 Swelling in lower limbs 
 Breathing difficulty 
 All of them were advised to maintain menstrual calendar in detail 
regarding the duration, number of pads soiled, clots passed and associated pain. 
Patients were asked to report any hysterectomy or subsequent surgery. 
Treatment considered failed if any symptom persisted / worsened after 
embolisation . 
Follow up: 
        At the end of 3
rd
 month all patients were called back and enquired about 
their menstruation, dysmenorrhoea and pressure symptom.  
 Three-Dimensional Trans Abdominal USG Pelvis and Three-Dimensional 
Color Doppler Sonography performed to know the size , volume and the 
vascularity of fibroid. The greatest decrease in vascularity occurred one day 
after the procedure. whereas the greatest volume reduction  was found  at the 
end of 3 month follow up. 
 Similarly at 6
th 
and 12
th
 month patients were again reviewed  enquired 
about   symptoms with  sonographic examination  to know the size, volume and 
the vascularity of fibroid . 
 
 ANALYSIS AND RESULTS 
 32 patients with uterine fibroid selected according to the inclusion 
criteria were taken up for the study.   
Evaluation of clinical symptoms was classified as increased, unchanged, 
improved, or absent (i.e., symptom-free).  
Sonographic examinations were always performed using a 3.5-MHz 
three dimensional trans abdominal probe with color Doppler sonography 
(SIEMENS ACUSON ANTARES MACHINE). Findings was analyzed by 
measuring the size,  volume  and   vascularity of the fibroid. 
Successful embolization was done in 30 patients. For one patient 
catheterisation could not be done due to vasospasm on both sides and another 
patient had subintimal dissection during catheterisation, so procedure 
abandoned.  
We therefore analysed the data for 30 patients but 3 patients was lost to 
follow up at 12 months so, for statistical calculation we have taken 27 samples.  
SIZE AND VOLUME : 
Size and volume of the fibroid is calculated by  three dimensional 
sonographic  examination. Volume of fibroid ranges from 38.23 - 220 cu cm. 
Average volume of fibroid before treatment is 113.02  cu .cm. Largest size of 
fibroid in our study is 220.32 cu.cm . In 2 cases of multiple fibroid the size of 
the largest fibroid is taken. volume distribution of fibroid is given below, 
Volume of fibroid         
(cu. cm) 
No of subjects % 
Small (<50) 6 20.00 
Medium (50 – 150) 16 53.33 
Large (>150) 8 26.66 
Total 30  
 
 
  
CATHETERISATION : 
Unilateral or bilateral selective uterine artery catheterization and 
embolization were carried out by unilateral transfemoral puncture,, successfully 
in all 30 patients.    
 No of subjects % 
Unilateral embolisation 19 70.37 
Bilateral embolisation 8 29.62 
Un successful 
catheterisation 
2 6.25 
Total 32  
 
 COMPLICATIONS: 
Procedure related : 
             Except for the subintimal dissection and vasospasm, no other 
complications occurred during the procedure. Fortunately we have not come 
across any major untoward events, infection, septicaemia, pulmonary 
embolism, fibroid passage, fibroid regrowth. Uterine necrosis, etc.  
 
 
NO COMPLICATION
VASOSPASM
SID
 
FOLLOW UP 
Clinical  Follow Up  :  
 All the 30 patients who had good clinical outcome, resumed normal 
menstrual cycle at 1–3 months.   
 One patient presented with fever and vaginal discharge 1 week 
after procedure.  
 Uterine ischemia causing pain found in all 30 patients ,treated 
with analgesics. 
 Post embolization syndrome55 in the form of abdominal 
discomfort, pain and fever was noted in 2 patients. These 
symptoms were transient and did not require any treatment except 
mild analgesics and antipyretics. 
ULTRASOUND FOLLOW UP: 
VOLUME CHANGES : 
Using  prolate ellipsoid formula
10
, fibroid  volume  is calculated in our  
study. 
        
 
Volume was  measured using the formula :   
length x width x depth x 0.5233 
When computed only  27 patients  came for 12 months follow up , so we 
have selected  n= 27 for comparison statistics, the mean reduction in fibroid 
volume were statistically significant. By using highly correlative  friedman’s  
test, volume change after 3 months, at 6 months and at 12 months was 
significant (P value  <0.001) with associated marked reduction in vascularity of 
all hypervascular fibroid. 
In larger volume (>150 cu.cm)  fibroids : volume reduction  was 42.24 
%  (range 32.61 - 50.25 %) at 3 months, at 6 months 76.22% (61.47 - 89.38 %) 
and at 12 months was  88.02 % (range  81.12 - 93.63 %).  
For  medium volume (50 -150 cu.cm)  )  fibroids : volume reduction  
was 47.90 %  (range 24.81- 67.04 %) at 3 months, at 6 months  72.48% (44.36  
-  89.12 %) and at 12 months was 83.86 % (range  61.85 - 93.24  %)  
For  smaller volume (< 50 cu.cm) )  fibroids : volume reduction  was 
42.24 %  (range 20.00- 59.60%) at 3 months, at 6 months 76.22% (35.36 - 
86.80 %) and at 12 months was   88.02 % (range  44.96- 91.92  %).  
On pre - UAE US, all  patient had fibroids that were mixed /hypo echoic 
and  were hypoechoic on post- UAE US scans.  
In this study moderate to marked reduction in larger fibroid volume was 
seen in 72.48% 83.86 % at 6 months, and 88% at 12 months respectively while 
using PVA with gelfoam combination. 
VASCULARITY ASSESSMENT  
In our study only hypervascular fibroid were  selected  and we have  
assessed reduced vascularity in them .  
 OVERALL RESULTS 
 
A. Three dimensional color Doppler sonographic examination  results 
of volume and vascularity assessment : 
 Median uterine fibroid size was reduced by 75 – 88%, better 
reduction is achieved in  
1. Bilateral approach – 88.32% 
2. Embolic agents (PVA +Gelfoam)  – 88.32% 
3. Large volume fibroid - 88.02% 
 Dominant fibroid size was reduced by 42% 
B.  Clinical improvement : 
 83% reduction in menorrhagia  
 77% reduction in dysmenorrhea  
 86% reduction in urinary frequency (Pressure symptoms). 
DESCRIPTIVES STATISTICS 
REDUCTION PERCENTAGE IN VOLUME OF FIBROIDS OVER 
TIME ASSESSMENT: 
TABLE :1 
(A) POST EMBOLISATION REDUCTION PERCENTAGE IN 
VOLUME OF FIBROIDS IN UNILATERAL VERSUS 
BILATERAL EMBOLISATION. 
REDUCTION PERIOD UNILATERAL BILATERAL 
After 3 months 43.33 47.34 
After 6 months 69.05 77.28 
After 12 months 80.86 88.32 
P value <0.001** <0.001** 
P value  < 0.001 
Note:  ** ---denotes significant at 1% level 
*   --denotes significant at 5% level. 
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TABLE : 2 
(B) POST EMBOLISATION REDUCTION PERCENTAGE IN  
VOLUME OF FIBROIDS WITH DIFFERING EMBOLIC 
AGENTS. 
REDUCTION PERIOD GELFOAM PVA + GELFOAM 
After 3 months  37.61 50.04 
After 6 months  65.30 76.44 
After 12 months  77.76 87.31 
P value  <0.001** <0.001** 
P value  < 0.001 
Note:  ** ---denotes significant at 1% level 
*   --denotes significant at 5% level. 
MATERIALS USED
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TABLE : 3 
(C) POST EMBOLISATION REDUCTION PERCENTAGE IN  
VOLUME OF FIBROIDS IN  DIFFERING PRE EMBOLISATION 
FIBROID VOLUME CATEGORIES. 
Volume category 
Small 
(<50 cu.cm) 
Medium 
(50-150 cu.cm) 
Large 
(>150 cu.cm) 
After 3 months  37.55 47.90 42.24 
After 6 months  61.88 72.48 76.22 
After 12 months  73.75 83.86 88.02 
P value  <0.001** <0.001**      <0.001** 
P value  < 0.001 
Note:  ** ---denotes significant at 1% level 
*   --denotes significant at 5% level 
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OVER ALL RESULTS 
 (D) POST EMBOLISATION REDUCTION PERCENTAGE IN 
VOLUME OF FIBROIDS IN OVERALL ASSESSMENT. 
Reductio
n Period 
Unilateral Bilateral Gelfoam 
PVA + 
Gelfoam 
Smaller 
volume 
Medium 
volume 
Large 
volume 
After 3 
months  
43.33 47.34 37.61 50.04 37.55 47.90 42.24 
After 6 
months  
69.05 77.28 65.30 76.44 61.88 72.48 76.22 
After 12 
months  
80.86 88.32 77.76 87.31 73.75 83.86 88.02 
P value  
<0.001** <0.001** 
<0.001*
* 
<0.001** <0.001** <0.001** 
     
<0.001** 
 
P value  < 0.001 
Note:  ** ---denotes significant at 1% level 
*   --denotes significant at 5% level. 
DISCUSSION 
 Fibroid uterus causing menorrhagia is one of the common morbidity 
encountered in the women of child bearing age group. Hence many young 
women opt to undergo hysterectomy at an early age. Uterine artery 
embolisation is minimally invasive alternative primary treatment of fibroids 
with preservation of uterus.   
 This study was done to assess the efficacy of uterine artery embolisation 
with three dimensional color doppler sonography. Pre embolization and 
postembolization three-dimensional
 
color Doppler sonography was 
prospectively compared in 30 patients who underwent uterine
 
artery 
embolization as primary  treatment of symptomatic fibroids.  
3D CDS has recently become available to quantify vascularity that gives 
good correlation to vessels greater than 100 micrometer. Three-dimensional
 
color Doppler sonography was performed by using a scanner with
 
color power 
angiographic imaging capability.   
For purposes of comparison,
 
fibroids were classified as either 
hypervascular or hypovascular relative to myometrial vascularity before and 
minutes to several
 
hours after uterine artery embolization. Changes in fibroid
 
vascularity (i.e., from hypervascular to hypovascular) as depicted
 
by three-
dimensional color  Doppler sonography  are   stated in Edwin F
 9
 Med   2005. 
Totally 32 samples were selected for the study, according to the 
inclusion and exclusion criteria. Of which  for   2 patients embolisation could 
not be done because of subintimal dissection and vasospasm happened during 
the procedure. Uterine
 
artery embolisation was performed by using a standard 
selective
  
catheter  and standard  embolization technique. Successful 
embolisation was done for 30 patients. Hence we have followed   30 patients 
upto  12 months to assess the changes in vascularity .  
In this study we have done both unilateral and bilateral UAE, where 
bilateral embolisation proved statistically significant (P value < 0.001**). In 
contrast, Edwin F, Arthur C. Fleischer, et al
9
, in their 2005
 
 study,  did 
unilateral UAE for all patients. Also  TP Jain, DN  Srivastava  etal
55  
2007, 
demonstrated that Ipsilateral  catheterization of uterine artery was  safe, cost-
effective and with lesser incidence of complications  such as haematoma and 
dissection of arteries.  
Uterine artery embolization is an effective and established treatment  
method to control intractable bleeding, C. Fleischer, et al
 
2005
9 
due to various 
other obstetric and gynaecological disorders.  Uterine fibroid embolisation acts 
mainly by occluding the blood supply to the tumour thus it arrests the growth 
and cause ischemia and necrosis. This causes shrinkage of the tumour and stops 
appearance of new fibroids as per long term follow up studies 
55
.  
Duration of the procedure varied from 45 minutes to 75 minutes. The 
average duration of the procedure was 65 minutes. This is comparable with 
results of previous researches.  
Radiation dose : 9-20 cgy in 1–2 hours procedure. 
The mean total procedure time as reported by other investigators has 
been 78.4 min for bilateral approach
 
and 44.29 and 61min for unilateral 
approach. In this study intermittent fluoroscopy was used to reduce the 
exposure. Fluoroscopic exposure time was 45 min, which is more compared 
with  Boris nikolic MD, james b, et al 
65
 2001. 
In  this study, average volume of fibroid before embolisation is 113.02 
cu.cm. (ranges 38.23 - 220 cu. cm). Largest fibroid volume in the study 
population was 220.32 cu.cm. In our series we have not encountered any 
additional complications in larger fibroids. This correlates with the recent study 
by Albert J. Smeets Robbert,et al
3
, 2009, which depicts that the  complications 
were not increased and  the clinical response is also good.  
Small size fibroid (less than 7 cm) show better response in size 
reduction and symptomatically feel better. Less than 1 percent of patients 
undergo hysterectomy due to embolisation failure, Jean-Pierre Pelage et al 
23 
2005. 
The greatest decrease in vascularity occurred 1 day after the procedure, 
whereas the greatest volume change was found at 3 month follow-up 
examination agreeing with the results depicted by Arthur C. Fleischer, F. 
Donnelly., et al
9
 in 2000. This statement correlates well in our study, selected 
hypervascular fibroids showed marked reduction in vascularity. 
In another study, hyper vascular fibroids (12 of 30) tended to  decrease 
in  size  after treatment more than isovascular (10 of 30) or hypovascular (8 of 
30). In our study most fibroids were hypervascular before UAE and became 
hypovascular after UAE as depicted by Arthur C. Fleischer,  MD, Edwin F
 
 
Med  2005
9
.  
Jean-Pierre Pelage et al 
23 
2005 states that  the main reason for not 
embolizing  the pedunculated fibroids is the potential risk of postprocedural 
torsion and is also stated in Laurent  Brunereau   Denis   Herbreteau  et al
30
,  
2002, who reported  sudden and massive necrobiosis changes in the embolised 
fibroids . 
Bruce McLucas, Rita Perrella, et al,
9  
states that largest myoma diameter 
of greater than 8 cm, PSV values of greater than 64cm/s during screening was  
found associated with  UFE failure.  In contrast, our study  could not find any  
significant potential in accurately predicting  the UAE failure . 
Ultrasound is faster, widely available  and cheaper, Three dimensional 
color doppler are more accurate  and reproducible .It is better  in  selecting 
patients  for UFE  and  also best response  assessment, Arthur C. Fleischer, 
MD, Edwin F
 
 Med, 2000, 2005
9
. 
Previous  study shows MR imaging is sub optimal in  assessment of 
fibroid  volume, but  reliably detect adenomyosis  as given by  Edwin F, Arthur 
C. Fleischer, et al 
9 
2005. In our study we have not done MR imaging  
correlation  for all patients as it is not  accurately  depicting quantification of 
vascularity. 
Uterus always has the capacity to develop new leiomyomas after 
endovascular embolization with 150- to 250 micrometer  particles  Sangeet 
Ghai, et al,
2  
2005. Several Studies shows that PVA injection followed by 
gelfoam shows better results than with gelfoam used alone. Gelfoam Vs Poly 
Vinyl Alcohol is an  ideal embolic agent in UAE . 
Among 30 patients in the study 14 of them were embolised with gel 
foam and remaining 16 was embolised with poly vinyl alcohol particles of 350-
500 µm size followed by gelfoam. On analysing the volume reduction, both 
was equally effective with comparative higher statistical significant (p value 
<0.001) results with PVA followed by gelfoam. This result is comparable with 
Katz et al
26 
1998 who studied the effectiveness of gelatin sponge pledgets 
versus polyvinyl alcohol for embolization. They concluded that materials are 
equally effective. This result is in contrary to the statement by Jean-Pierre 
Pelage et al 
23 
2005, for targeted embolisation of the perifibroid arterial plexus, 
injection of PVA particles with diameter larger than 500 micrometer is 
recommended.  
 Studies by Derdelyn and Pelage et al
64
, 2001 have shown that Tris-acryl 
microspheres  are more uniform in size and the particle sizes do not changed in 
liquids. They have little tendency to clump after injection and animal studies 
indicate that they have less tissue reaction than is typically seen with PVA . 
As in C. Joseph Muniz, MD, Arthur C. et al
6
 , 2002 our study analysis 
showed  that almost all of the  patients were clinically improved at 3 months, 6 
months, and 1 year, and  all were symptom-free at 1 years. Sonography was an 
ideal method to show and follow the progressive reduction in the size of the 
main leiomyoma procedure as proved by  Laurent  Brunereau   Denis  
Herbreteau  et al ,
30
  in 2000.   
Remarkable  average Volume Reduction at the 3
rd
 month  especially  in 
larger volume (>150 cu.cm)  of  fibroid was 42.24 %  (range 32.61 - 50.25 %) 
at 3 months,  at 6 months  76.22% (61.47 -  89.38 %) and   at 12 months was   
88.02 % (range  81.12 - 93.63 %) (p<0.0001 highly significant).  It is 
comparable with that seen in the study by Spies JB, Scialli AR,  et al 53 in 1999  
who has reported 50% reduction at 6
th
 month and 78% reduction  at 1
st
 year. 
All patients should be monitored with clinical and sonographic 
examinations for more than 2 years after the endovascular procedure, 
Embolization cannot therefore be considered a radical treatment compared with 
hysterectomy, depicted by Laurent  Brunereau   Denis  Herbreteau  et al,
30
  in 
2000. 
Jean-Pierre Pelage et al
23 
2005; Vaginal discharge and fibroid expulsion 
are more common with intramural fibroid. 
Overall, the information regarding fibroid vascularity ideally obtained 
on 3D CDS may be useful in determining which patients are best suited for 
UAE therapy
9
. 3D CDS is less expensive and more extensively available and 
can depict actual vessels within and surrounding fibroids . Good results of  
UAE were seen in a larger volume hypervascular fibroids approached  
bilaterally with  PVA followed by gelfoam embolic agents. 
LIMITATIONS 
1. For one patient catheterisation could not be done due to vasospasm on 
both sides and another patient had subintimal dissection during 
catheterisation, so procedure abandoned.  
2. Since all 30 patients, responded to fibroid embolization, it is not 
possible from data acquired in this small series to come to any 
conclusions regarding the use of 3D CDS for predicting which patients 
will be responders or nonresponders
 
.  
3. Few patients have  lost  their long term follow up at 12 months or later  
of  post embolisation. 
CONCLUSION 
* From this study we have found that Uterine Artery Embolisation for the 
patients having symptomatic uterine fibroid is an effective and safe 
alternate treatment with significant reduction in volume and vascularity 
of fibroid particularly in less than 7 cm fibroids. 
* Three dimensional color Doppler sonography assists in assessing the 
vascularity within the fibroid before and after embolisation.  
* Single trans femoral approach with bilateral uterine arteries 
embolisation technique was used successfully in most of our patients.  
Combined PVA - Gelfoam is one of the ideal embolic agents effective in 
causing volume and vascularity reduction along with relief of the 
symptoms in patients with fibroid. Hypervascular fibroid respond well 
to embolisation . It has less failure rates in long term follow up. This 
procedure has good patient’s tolerance, short recovery time, quick and 
sustained symptomatic improvement.  This procedure may reduce the 
need for invasive surgery in many patients.  
* From this study we conclude that Three Dimensional Color Doppler 
Imaging can be a tool for pre and post UAE evaluation in assessing 
reduction in fibroid vascularity and volume. It is less expensive, more 
extensively available and provides an estimate of completeness of 
embolisation. 
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PROFORMA 
 
Name: 
 
Indication for UFE: opted / anaemia / previous surgeries / obesity / others 
 
Age (yrs):     25-30       31-35       35-40        
 
History:  
 Menorrhagia - Assessed by Pictoral Blood Loss Assessment Chart 
 Dysmenorrhoea – Assessed by Visual Analogue Scale 
 Pressure Symptoms:   Yes/no 
 Increased frequency and urgency: Yes/no 
 Lower abdominal heaviness: Yes/no 
 Constipation: Yes/no 
 Marital status: married/unmarried 
 Obstetric history: No of children    Nil /  1 / 2 /  >2 
 History of Allergy: Yes/no 
 History of previous surgeries: Yes / No 
Clinical Examination: 
 General Examination: 
 Height :  Weight:  BMI: 
 Anaemia: 
 Peripheral edema:  
 Miscellaneous: 
 CVS: 
 RS: 
 Abdomen: 
 Gynaecological Examination: 
 Speculum examination: 
 P/V: 
Investigations 
 Hb%: 
 Blood sugar :          
 Urea:              Sr. creatinine:  
 TC :               DC:                 ESR: 
 HIV: 
 HbsAg: 
 BT:     CT: 
 
Fractional Curettage Report: 
PAP smear: 
 
USG: 
 Mean Uterine sizes: 
 No. of fibroids: 
 Size of fibroids: 
 Largest axis of largest fibroid: 
 Volume of fibroid: 
 Calcification / degeneration: 
 
Doppler: 
 hypovascular / hypervascular 
 
Uterine Artery Embolisation: 
Done on: 
Duration of procedure: 
Catheterisation: unilateral  
Embolisation: No / unilateral / bilateral 
Embolic particle used: Gel foam /PVA+Gelfoam 
Complication During procedure:  
 Vasospasm :Yes/No 
 Vascular-perforation :Yes/No 
 Subintimal-dissection :Yes/No 
 Allergy :Yes/No 
 Mis-embolisation :Yes/No 
 Miscellaneous. 
Immediate post procedure complications  
 Pain :Yes/No 
 Vomiting :Yes/No 
 Post  embolic syndrome :Yes/No 
 Deep  vein thrombosis :Yes/No 
Late complication 
 Vaginal discharge :Yes/No 
 Fever :Yes/No 
 Trans cervical expulsion :Yes/No 
 Amenorrhoea :Yes/No 
Patient discharged on: 
Follow up at 3months: 
 Menstrual blood loss: 
 Dysmenorrhea: 
 Pressure symptom: 
Transabdominal and Three-Dimensional Color Doppler Sonography: 
 Fibroid size   :                                 
 Volume: 
 Vascularity :  
Follow up at 6months: 
 Menstrual blood loss: 
 Dysmenorrhea: 
 Pressure symptom: 
Transabdominal and Three-Dimensional Color Doppler Sonography: 
 Fibroid size   :                                 
 Volume: 
 Vascularity :  
Follow up at 12 months: 
 Menstrual blood loss: 
 Dysmenorrhea: 
 Pressure symptom: 
Transabdominal and Three-Dimensional Color Doppler Sonography: 
 Fibroid size   :                                 
 Volume: 
 Vascularity :  
 
  
ABBREVATIONS 
 
UAE   - Uterine Artery Embolization 
UFE    - Uterine Fibroid Embolization 
3D  CDS   - Three-Dimensional  Color Doppler  
    Sonography 
UAA    - Uterine Artery Arteriography 
LMP   - Last menstrual period 
PBLA Scoring  - Pictorial Blood Loss Assessment Scoring 
VAS    - Visual Analogue Scale 
USG    - Ultrasound 
PES    - PostEmbolisation Syndrome 
AVMs   - Arterio Venous Malformations 
PES   - Post embolisation syndrome 
GF   - Gel Foam 
PVA   - Poly Vinyl Alcohol 
SID   - Subintimal dissection 
VS   - Vasospasm 
CASE: 1 
 
 
 
 
 
 
 
PRE EMBOLISATION – GREY SCALE IMAGE ULTRASONOGRAPHY   
VOLUME MEASURES 164.27 cu. cm 
 
 
 
 
 
 
 
 
PRE EMBOLISATION - 3D COLOR DOPPLER SHOWS 
HYPER VASCULAR FIBROID  
UTERINE ARTERY EMBOLISATION 
FLUSH AORTIC ANGIOGRAM TO DETECT ABBERRANT VASCULAR 
SUPPLY 
 
 
 
 
 
 
 
 
CONTRALATERAL PELVIC ANGIOGRAM VIA LEFT TRANSFEMORAL 
APPROACH 
 
 
 
 
 
 
 
 
IPSILATERAL PELVIC       SUPER SELECTIVE ANGIOGRAM 
     ANGIOGRAM     OF UTERINE ARTERIES 
 
 
 
 
 
 
 
 
 
 
 
ARTERIAL PHASE  OF CONTRAST      VENOUS PHASE OF CONTRAST 
 
 
 
 
 
 
 
               POST EMBOLISATION  
STANDING COLUMN OF  
      DURING EMBOLISATION     CONTRAST 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
POST-EMBOLIZATION PELVIC ANGIOGRAPHY PERFORMED TO 
DOCUMENT ARTERIAL  OCCLUSION 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
POST EMBOLISATION  3 MONTHS FOLLOW UP IMAGE  
42.24% VOLUME REDUCTION DETECTED 
Embolic agent in fibroid  
 
NO FLOW INSIDE FIBROID  
 
IMMEDIATE  POST EMBOLISATION GREY 
SCALE IMAGE 
 
 
IMMEDIATE   POST EMBOLISATION  3D COLOR DOPPLER IMAGE  
SHOWING HYPO VASCULARITY 
  
 
 
 
 
 
 
POST EMBOLISATION 6 MONTHS FOLLOW UP 3 D IMAGE      
76.22%   VOLUME REDUCTION DETECTED 
 
 
 
 
 
 
 
POST EMBOLISATION 12 MONTHS FOLLOW UP  3D  COLOR DOPPLER - 
88.02% VOLUME REDUCTION DETECTED AND HYPOVASCULAR 
 
CASE - 2 
 
 
 
 
 
PRE EMBOLISATION – GREY SCALE IMAGE ULTRASONOGRAPHY - 
VOLUME MEASUREMENT - 147 cu.cm 
 
 
 
 
 
 
 
 
PRE EMBOLISATION - 3D COLOR DOPPLER SHOWING 
HYPERVASCULAR FIBROID 
UTERINE ARTERY EMBOLISATION 
EMBOLISATION IN A PATIENT WITH PELVIC KIDNEY 
 
 
 
 
 
 
 
 
 
 
 
 
SUPER SELECTIVE ANGIOGRAM OF  IPSILATERAL LEFT UTERINE ARTERY 
 
 
 
 
POST-EMBOLIZATION PELVIC ANGIOGRAPHY SHOULD BE PERFORMED TO 
DOCUMENT ARTERIAL  OCCLUSION 
  
 
 
 
 
 
IMMEDIATE POST EMBOLISATION  - COLOUR DOPPLER IMAGE  -  
SHOWING HYPOVASCULARITY 
 
 
 
 
 
 
 
 
 
  POST EMBOLISATION 3 MONTHS FOLLOW UP COLOR DOPPLER IMAGE  -  
47.90%  VOLUME REDUCTION DETECTED AND HYPOVASCULAR 
 
  
 
 
 
 
 
 
 
POST EMBOLISATION 6 MONTHS FOLLOW UP IMAGE – 
72.48%   VOLUME REDUCTION DETECTED AND HYPOVASCULAR 
 
 
 
 
 
 
 
 
 
 
POST EMBOLISATION 12 MONTHS FOLLOW UP IMAGE -    
83.86 %   VOLUME REDUCTION DETECTED AND HYPOVASCULAR 
CASE - 3 
 
 
 
 
 
 
 
 
 
 
PRE  EMBOLISATION  3D COLOR DOPPLER   IMAGE  
98 cu. cm VOLUME DETECTED AND HYPER VASCULAR FIBROID 
 
 
 
 
 
 
 
 
 
SELECTIVE IPSILATERAL RIGHT UTERINE ARTERY ANGIOGRAM VIA 
RIGHT TRANSFEMORAL APPROACH 
  
 
 
 
 
 
 
 
 
 
 
VENOUS PHASE OF UTERINE ARTERY ARTERIOGRAPHY 
 
 
 
 
 
 
 
 
 
 
 
 
DURING PVA PARTICLES  EMBOLISATION OF RIGHT UAE  
  
 
 
 
 
 
 
 
DURING GEL FOAM INJECTION OF RIGHT MAIN UTERINE ARTERY 
 
 
 
 
 
 
 
 
 
POST EMBOLISATION STANDING COLUMN OF CONTRAST 
 
POST EMBOLISATION  
 
 
 
IMMEDIATE POST 
EMBOLISATION GREY SCALE   
IMAGE  -  VOLUME 
MEASURING 102 cu. cm 
 
 
 
 
 
 
 
 
 
 
 
 
 
POST EMBOLISATION   
3 MONTHS FOLLOWUP   
IMAGE - 38% VOLUME 
REDUCTION AND 
HYPOVASCULAR 
 
POST EMBOLISATION  6 
MONTHS FOLLOWUP  
IMAGE –  65.7% VOLUME 
REDUCTION AND 
HYPOVASCULAR 
 
  
 
 
 
 
 
 
POST EMBOLISATION   12 MONTHS  3D CDS SONOGRAPHIC  IMAGE – 
80 %VOLUME REDUCTION AND HYPOVASCULAR 
 
 
 
 
 
 
 
 
POST EMBOLISATION  12 MONTHS  3D COLOR DOPPLER   IMAGE 
SHOWING MARKED REDUCTION IN VASCULARITY 
CASE - 4 
 
 
 
 
 
 
PRE  EMBOLISATION  LEFT UTERINE ARTERY PSV – 44.1 cm/s 
 
 
 
 
 
 
PRE  EMBOLISATION RIGHT UTERINE ARTERY PSV – 27.7 cm/s 
 
 
 
 
 
PRE  EMBOLISATION  3D COLOR DOPPLER IMAGE 
EMBOLISATION OF RIGHT SIDE UTERINE ARTERY VIA LEFT 
TRANSFEMORAL APPROACH 
 
 
 
 
 
 
IMMEDIATE POST EMBOLISATION GREY SCALE  IMAGE    
 
 
 
 
 
POST EMBOLISATION 12 MONTHS FOLLOW UP GREY SCALE  IMAGE   -  
78% VOLUME REDUCTION DETECTED AND HYPOVASCULAR FIBROID 
 
 
 
 
 
 
CASE - 5 
 
 
 
 
 
 
 
2D FIBROID DETECTION  
 
 
 
 
 
 
 
 
PRE  EMBOLISATION 3D COLOR DOPPLER – 
VOLUME MEASURES 109.23 cu.cm AND HYPERVASCULAR FIBROID 
 
UTERINE ARTERY EMBOLISATION 
 
 
 
 
 
 
POST EMBOLISATION LEFT PELVIC ANGIOGRAM  WITH STANDING  
COLUMN OF CONTRAST 
 
 
 
 
 
 
IMMEDIATE POST EMBOLISATION – GREY SCALE IMAGE SHOWING 
HYPERECHOEIC EMBOLIC AGENTS 
 
 
 
 
 
POST EMBOLISATION FOLLOW UP 3 MONTHS GREY SCALE  IMAGE 
SHOWING 40% VOLUME REDUCTION 
  
 
 
 
 
 
 
 
 
POST EMBOLISATION  6 MONTHS 3D COLOR DOPPLER  FOLLOWUP 
63% VOLUME REDUCTION AND HYPO VASCULAR FIBROID 
 
 
 
 
 
 
 
 
POST EMBOLISATION  12 MONTHS FOLLOW UP    
81% VOLUME REDUCTION AND HYPO VASCULAR FIBROID 
 
 
 
Sl.No. patient no Age / Sex Indication Pressure Approach Uni/Bi Particles Used Vol_bef Vol_3m Vol_6m Vol_12m
1 1
35/f
previous surgery NO
Right TFA unilateral gelfoam
164.75 98.68 17.50 10.50
2 2
40/F
OPTED NO
Right TFA unilateral gelfoam
136.66 102.00 76.04 33.04
3 3
38/f
OPTED yes
Right TFA unilateral gelfoam
51.78 37.07 33.47 28.50
4 4
40/f
OPTED NO
Right TFA unilateral gelfoam
51.40 30.95 21.97 16.50
5 5
35/f
OPTED NO
Right TFA unilateral gelfoam
149.14 79.88 75.50 56.90
6 6
35/f
OPTED yes
Right TFA Unilateral Gelfoam
60.00 32.00 18.36 10.90
7 7
40/f
ANEMIA NO
Right TFA Unilateral PVA+ Gelfoam
38.23 22.00 10.81
8 8
40/F
OPTED NO
Right TFA bilateral PVA+ Gelfoam
94.87 32.62 20.00 12.00
9 9
39/f
OPTED NO
Right TFA Unilateral PVA+ Gelfoam
162.75 89.88 32.48 26.90
10 10
30/f
OPTED yes
Right TFA Bilateral PVA+ Gelfoam
109.23 65.93 30.23 10.07
11 11
40/f
ANEMIA NO
Right TFA Unilateral Gelfoam
94.87 42.00 31.16 20.70
12 12
40/f
OPTED NO
Right TFA Bilateral Gelfoam
44.55 18.00 5.88 3.90
13 13
40/f
OBESE NO
Right TFA Bilateral Gelfoam
60.00 40.00 9.91
14 14
40/f
OPTED NO
Right TFA Bilateral Gelfoam
66.25 37.66 13.48 6.30
15 15
40/f
ANEMIA NO
Right TFA Unilateral PVA
68.75 30.01 23.06 13.40
16 16
40/f
OPTED NO
Left TFA Bilateral PVA+ Gelfoam
147.00 58.00 28.86 14.20
17 17
38/f
ANEMIA NO
Right TFA Bilateral Gelfoam
52.30 37.66 18.36 13.20
18 18
34/f
OPTED NO
B/l TFA Bilateral Gelfoam
50.00 30.00 12.04 4.04
19 19
35/f
heart disease NO
B/l TFA Bilateral Gelfoam
122.38 92.02 25.19 12.60
20 20
38/f
OPTED yes
B/l TFA unilateral PVA+ Gelfoam
206.08 138.88 51.30 38.90
21 21
40/f
previous surgery yes
B/l TFA unilateral PVA+ Gelfoam
102.00 53.20 11.10 6.90
22 22
40/f
previous surgery NO
B/l TFA unilateral PVA+ Gelfoam
67.85 27.04 9.85 5.90
23 23
37/f
OPTED no
B/l TFA unilateral PVA+ Gelfoam
190.08 103.73 73.23 18.04
24 24
38/f
anaemic yes
B/l TFA unilateral PVA+ Gelfoam
128.76 71.74 27.55 20.30
25 25
40/f
OPTED no
B/l TFA unilateral PVA+ Gelfoam
156.87 94.79 22.59 15.30
26 26
39/F
OPTED NO
B/l TFA unilateral PVA+ Gelfoam
131.95 56.09 22.46 16.30
27 27
40/F
OBESE NO
B/l TFA unilateral PVA+ Gelfoam
150.50 74.88 34.03 13.07
28 28
37/F
OPTED NO
B/l TFA unilateral PVA+ Gelfoam
132.24 71.73 42.06 24.05
29 29
35/F
OPTED NO
B/l TFA unilateral PVA+ Gelfoam
199.68 101.75 58.30
30 30
40/F
OPTED NO
B/l TFA unilateral PVA+ Gelfoam
220.32 125.59 78.02 31.03
